Search

Your search keyword '"Pei, York"' showing total 537 results

Search Constraints

Start Over You searched for: Author "Pei, York" Remove constraint Author: "Pei, York"
537 results on '"Pei, York"'

Search Results

1. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group

2. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

7. Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease

9. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

12. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group

21. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption

22. PKHD1 Protein Encoded by the Gene for Autosomal Recessive Polycystic Kidney Disease Associates with Basal Bodies and Primary Cilia in Renal Epithelial Cells

26. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial

27. Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging

33. Isolated polycystic liver disease genes define effectors of polycystin-1 function

36. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

38. Polycystic Kidney Disease without an Apparent Family History

39. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency

40. Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease.

42. Atypical Polycystic Kidney Disease by Imaging

49. GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy

50. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy

Catalog

Books, media, physical & digital resources